Stem definition | Drug id | CAS RN |
---|---|---|
antifungal antibiotics | 1798 | 235114-32-6 |
Dose | Unit | Route |
---|---|---|
0.10 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.30 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.21 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.17 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 16 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 16, 2005 | FDA | FUJISAWA HLTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 201.23 | 25.45 | 135 | 6273 | 97532 | 50501184 |
Pre-engraftment immune reaction | 170.31 | 25.45 | 29 | 6379 | 209 | 50598507 |
Human herpesvirus 6 infection | 157.17 | 25.45 | 41 | 6367 | 2565 | 50596151 |
Encephalitis viral | 145.68 | 25.45 | 35 | 6373 | 1562 | 50597154 |
Multiple organ dysfunction syndrome | 114.17 | 25.45 | 74 | 6334 | 50263 | 50548453 |
Cytomegalovirus test positive | 105.86 | 25.45 | 30 | 6378 | 2562 | 50596154 |
Acute graft versus host disease | 93.33 | 25.45 | 30 | 6378 | 3928 | 50594788 |
Sepsis | 84.98 | 25.45 | 94 | 6314 | 132831 | 50465885 |
Acute graft versus host disease in skin | 84.15 | 25.45 | 26 | 6382 | 2992 | 50595724 |
Bacterial sepsis | 79.56 | 25.45 | 26 | 6382 | 3586 | 50595130 |
Pneumonia fungal | 78.88 | 25.45 | 27 | 6381 | 4293 | 50594423 |
Aplastic anaemia | 77.27 | 25.45 | 31 | 6377 | 7672 | 50591044 |
Hepatic function abnormal | 69.06 | 25.45 | 46 | 6362 | 32635 | 50566081 |
Aspergillus infection | 66.86 | 25.45 | 27 | 6381 | 6794 | 50591922 |
Thrombotic microangiopathy | 66.72 | 25.45 | 29 | 6379 | 8762 | 50589954 |
Cytomegalovirus viraemia | 65.32 | 25.45 | 24 | 6384 | 4685 | 50594031 |
Mucormycosis | 63.40 | 25.45 | 20 | 6388 | 2463 | 50596253 |
Engraft failure | 60.91 | 25.45 | 13 | 6395 | 337 | 50598379 |
Septic shock | 59.91 | 25.45 | 53 | 6355 | 57122 | 50541594 |
Gastrointestinal fungal infection | 58.46 | 25.45 | 12 | 6396 | 256 | 50598460 |
Cytomegalovirus infection | 57.62 | 25.45 | 33 | 6375 | 17929 | 50580787 |
Meningoencephalitis herpetic | 55.73 | 25.45 | 15 | 6393 | 1057 | 50597659 |
Pyrexia | 55.04 | 25.45 | 137 | 6271 | 380066 | 50218650 |
Bronchopulmonary aspergillosis | 54.22 | 25.45 | 24 | 6384 | 7568 | 50591148 |
Off label use | 53.67 | 25.45 | 156 | 6252 | 474270 | 50124446 |
Graft versus host disease | 52.26 | 25.45 | 22 | 6386 | 6144 | 50592572 |
Sinus polyp | 50.76 | 25.45 | 11 | 6397 | 307 | 50598409 |
Pathogen resistance | 50.58 | 25.45 | 21 | 6387 | 5668 | 50593048 |
Product use in unapproved indication | 49.67 | 25.45 | 67 | 6341 | 115752 | 50482964 |
Enterococcal sepsis | 48.65 | 25.45 | 14 | 6394 | 1261 | 50597455 |
Respiratory failure | 47.33 | 25.45 | 58 | 6350 | 91123 | 50507593 |
Weissella infection | 47.20 | 25.45 | 7 | 6401 | 17 | 50598699 |
Liver abscess | 46.53 | 25.45 | 16 | 6392 | 2577 | 50596139 |
Systemic mycosis | 46.16 | 25.45 | 13 | 6395 | 1084 | 50597632 |
Platelet count decreased | 42.76 | 25.45 | 58 | 6350 | 100668 | 50498048 |
Aspartate aminotransferase increased | 42.73 | 25.45 | 51 | 6357 | 77947 | 50520769 |
Plasma cell leukaemia | 42.58 | 25.45 | 12 | 6396 | 1003 | 50597713 |
Hypoalbuminaemia | 42.40 | 25.45 | 22 | 6386 | 9838 | 50588878 |
Haemophagocytic lymphohistiocytosis | 42.19 | 25.45 | 21 | 6387 | 8612 | 50590104 |
Systemic candida | 41.60 | 25.45 | 15 | 6393 | 2775 | 50595941 |
Fatigue | 41.53 | 25.45 | 19 | 6389 | 707582 | 49891134 |
Disseminated intravascular coagulation | 40.79 | 25.45 | 26 | 6382 | 17109 | 50581607 |
Nasal abscess | 40.53 | 25.45 | 8 | 6400 | 139 | 50598577 |
Biloma | 40.02 | 25.45 | 7 | 6401 | 60 | 50598656 |
Enterobacter infection | 39.20 | 25.45 | 13 | 6395 | 1875 | 50596841 |
Acute myeloid leukaemia recurrent | 38.85 | 25.45 | 12 | 6396 | 1378 | 50597338 |
Fungaemia | 38.39 | 25.45 | 13 | 6395 | 1999 | 50596717 |
Encephalitis fungal | 37.62 | 25.45 | 6 | 6402 | 27 | 50598689 |
Arthralgia | 36.39 | 25.45 | 6 | 6402 | 438696 | 50160020 |
Mucosal erosion | 35.51 | 25.45 | 11 | 6397 | 1276 | 50597440 |
Alanine aminotransferase increased | 34.67 | 25.45 | 49 | 6359 | 88310 | 50510406 |
Chronic graft versus host disease | 33.89 | 25.45 | 13 | 6395 | 2854 | 50595862 |
Fungal infection | 33.82 | 25.45 | 29 | 6379 | 29936 | 50568780 |
Cytokine release syndrome | 33.54 | 25.45 | 18 | 6390 | 8616 | 50590100 |
Epstein-Barr virus associated lymphoproliferative disorder | 32.57 | 25.45 | 11 | 6397 | 1678 | 50597038 |
Enterococcal infection | 31.42 | 25.45 | 16 | 6392 | 6882 | 50591834 |
Trichosporon infection | 30.83 | 25.45 | 7 | 6401 | 243 | 50598473 |
Liver disorder | 30.29 | 25.45 | 30 | 6378 | 37192 | 50561524 |
Pain | 30.27 | 25.45 | 18 | 6390 | 578885 | 50019831 |
Cryptosporidiosis infection | 29.79 | 25.45 | 7 | 6401 | 283 | 50598433 |
Renal impairment | 29.74 | 25.45 | 42 | 6366 | 75619 | 50523097 |
Acute respiratory distress syndrome | 29.22 | 25.45 | 23 | 6385 | 21076 | 50577640 |
Drug ineffective for unapproved indication | 29.04 | 25.45 | 23 | 6385 | 21258 | 50577458 |
Acute graft versus host disease in intestine | 28.97 | 25.45 | 10 | 6398 | 1629 | 50597087 |
Aspergillus test positive | 28.87 | 25.45 | 7 | 6401 | 324 | 50598392 |
Pleural effusion | 28.79 | 25.45 | 43 | 6365 | 81411 | 50517305 |
Varicella zoster virus infection | 28.40 | 25.45 | 11 | 6397 | 2478 | 50596238 |
Oral fungal infection | 28.38 | 25.45 | 11 | 6397 | 2484 | 50596232 |
Mixed liver injury | 28.20 | 25.45 | 12 | 6396 | 3439 | 50595277 |
White blood cell count decreased | 27.05 | 25.45 | 51 | 6357 | 116671 | 50482045 |
Fall | 26.83 | 25.45 | 5 | 6403 | 334927 | 50263789 |
Blood bilirubin increased | 26.39 | 25.45 | 26 | 6382 | 32012 | 50566704 |
Dizziness | 26.04 | 25.45 | 6 | 6402 | 346363 | 50252353 |
Post transplant lymphoproliferative disorder | 25.93 | 25.45 | 12 | 6396 | 4192 | 50594524 |
Differentiation syndrome | 25.85 | 25.45 | 8 | 6400 | 925 | 50597791 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 174.50 | 19.82 | 206 | 10237 | 112034 | 29452050 |
Acute graft versus host disease in skin | 153.95 | 19.82 | 59 | 10384 | 4605 | 29559479 |
Aplastic anaemia | 145.78 | 19.82 | 65 | 10378 | 7445 | 29556639 |
Multiple organ dysfunction syndrome | 132.89 | 19.82 | 136 | 10307 | 62980 | 29501104 |
Bronchopulmonary aspergillosis | 104.47 | 19.82 | 61 | 10382 | 12283 | 29551801 |
Aspergillus infection | 102.20 | 19.82 | 57 | 10386 | 10524 | 29553560 |
Herpes simplex oesophagitis | 100.27 | 19.82 | 20 | 10423 | 119 | 29563965 |
Disseminated intravascular coagulation | 95.58 | 19.82 | 69 | 10374 | 19911 | 29544173 |
Graft versus host disease | 93.35 | 19.82 | 52 | 10391 | 9576 | 29554508 |
Acute graft versus host disease in intestine | 89.54 | 19.82 | 33 | 10410 | 2308 | 29561776 |
Cytomegalovirus viraemia | 89.50 | 19.82 | 44 | 10399 | 6276 | 29557808 |
Acute graft versus host disease | 86.83 | 19.82 | 42 | 10401 | 5782 | 29558302 |
Candida infection | 80.73 | 19.82 | 56 | 10387 | 15169 | 29548915 |
Cystitis haemorrhagic | 66.44 | 19.82 | 33 | 10410 | 4809 | 29559275 |
Trichosporon infection | 65.45 | 19.82 | 19 | 10424 | 621 | 29563463 |
Respiratory failure | 64.94 | 19.82 | 120 | 10323 | 97011 | 29467073 |
Mucormycosis | 64.47 | 19.82 | 33 | 10410 | 5125 | 29558959 |
Cytomegalovirus test positive | 64.40 | 19.82 | 29 | 10414 | 3394 | 29560690 |
Product use in unapproved indication | 64.04 | 19.82 | 112 | 10331 | 86763 | 29477321 |
Fungal infection | 62.57 | 19.82 | 46 | 10397 | 13639 | 29550445 |
Fungaemia | 59.34 | 19.82 | 24 | 10419 | 2157 | 29561927 |
Pyrexia | 57.08 | 19.82 | 226 | 10217 | 287396 | 29276688 |
Venoocclusive liver disease | 55.40 | 19.82 | 33 | 10410 | 6884 | 29557200 |
Acute graft versus host disease in liver | 55.40 | 19.82 | 20 | 10423 | 1318 | 29562766 |
Fatigue | 54.48 | 19.82 | 22 | 10421 | 316799 | 29247285 |
Fusarium infection | 53.19 | 19.82 | 18 | 10425 | 979 | 29563105 |
Pre-engraftment immune reaction | 52.31 | 19.82 | 11 | 10432 | 88 | 29563996 |
Sepsis | 50.79 | 19.82 | 137 | 10306 | 142545 | 29421539 |
Cytomegalovirus infection | 48.69 | 19.82 | 50 | 10393 | 23165 | 29540919 |
Septic shock | 46.50 | 19.82 | 81 | 10362 | 62479 | 29501605 |
Glomerulosclerosis | 46.43 | 19.82 | 15 | 10428 | 705 | 29563379 |
Acute myeloid leukaemia recurrent | 46.41 | 19.82 | 19 | 10424 | 1761 | 29562323 |
Human herpesvirus 6 infection | 45.58 | 19.82 | 19 | 10424 | 1844 | 29562240 |
Chronic graft versus host disease | 45.26 | 19.82 | 24 | 10419 | 4005 | 29560079 |
Staphylococcal sepsis | 43.26 | 19.82 | 31 | 10412 | 8831 | 29555253 |
Enterococcal infection | 42.85 | 19.82 | 30 | 10413 | 8238 | 29555846 |
Cytokine release syndrome | 42.50 | 19.82 | 36 | 10407 | 13083 | 29551001 |
Systemic candida | 41.28 | 19.82 | 20 | 10423 | 2760 | 29561324 |
Botulism | 41.22 | 19.82 | 10 | 10433 | 160 | 29563924 |
Hepatic function abnormal | 40.41 | 19.82 | 59 | 10384 | 39200 | 29524884 |
Dizziness | 40.08 | 19.82 | 9 | 10434 | 189675 | 29374409 |
Encephalitis viral | 39.79 | 19.82 | 15 | 10428 | 1117 | 29562967 |
Haemophagocytic lymphohistiocytosis | 36.46 | 19.82 | 30 | 10413 | 10474 | 29553610 |
Systemic mycosis | 34.10 | 19.82 | 14 | 10429 | 1307 | 29562777 |
Cholestatic liver injury | 33.91 | 19.82 | 15 | 10428 | 1682 | 29562402 |
Rhinocerebral mucormycosis | 32.68 | 19.82 | 9 | 10434 | 242 | 29563842 |
Graft versus host disease in gastrointestinal tract | 32.67 | 19.82 | 18 | 10425 | 3240 | 29560844 |
Off label use | 32.57 | 19.82 | 199 | 10244 | 300601 | 29263483 |
Pneumonia fungal | 32.38 | 19.82 | 22 | 10421 | 5755 | 29558329 |
Geotrichum infection | 31.69 | 19.82 | 10 | 10433 | 435 | 29563649 |
Kidney fibrosis | 31.22 | 19.82 | 15 | 10428 | 2032 | 29562052 |
Immunosuppressant drug level increased | 31.21 | 19.82 | 20 | 10423 | 4745 | 29559339 |
Fall | 30.87 | 19.82 | 12 | 10431 | 177166 | 29386918 |
Cystitis viral | 30.24 | 19.82 | 10 | 10433 | 506 | 29563578 |
Necrotising oesophagitis | 30.13 | 19.82 | 10 | 10433 | 512 | 29563572 |
Drug ineffective | 29.62 | 19.82 | 224 | 10219 | 362946 | 29201138 |
Graft versus host disease in skin | 29.37 | 19.82 | 17 | 10426 | 3362 | 29560722 |
Candida sepsis | 29.32 | 19.82 | 12 | 10431 | 1111 | 29562973 |
Drug resistance | 29.18 | 19.82 | 37 | 10406 | 21503 | 29542581 |
Renal failure | 29.08 | 19.82 | 100 | 10343 | 118499 | 29445585 |
Delayed graft function | 29.03 | 19.82 | 14 | 10429 | 1913 | 29562171 |
Mucosal disorder | 28.98 | 19.82 | 13 | 10430 | 1507 | 29562577 |
Bacteraemia | 28.65 | 19.82 | 32 | 10411 | 16291 | 29547793 |
Myocardial infarction | 28.32 | 19.82 | 3 | 10440 | 110293 | 29453791 |
Idiopathic pneumonia syndrome | 28.27 | 19.82 | 8 | 10435 | 238 | 29563846 |
Platelet count decreased | 28.09 | 19.82 | 91 | 10352 | 104581 | 29459503 |
Pseudomembranous colitis | 27.85 | 19.82 | 15 | 10428 | 2582 | 29561502 |
Cerebral aspergillosis | 27.14 | 19.82 | 12 | 10431 | 1344 | 29562740 |
Reactive gastropathy | 26.71 | 19.82 | 7 | 10436 | 155 | 29563929 |
Thymus hypoplasia | 26.50 | 19.82 | 7 | 10436 | 160 | 29563924 |
Lymphoid tissue hypoplasia | 26.50 | 19.82 | 7 | 10436 | 160 | 29563924 |
Mucosal inflammation | 26.22 | 19.82 | 43 | 10400 | 31552 | 29532532 |
Enterococcal sepsis | 25.97 | 19.82 | 12 | 10431 | 1490 | 29562594 |
Functional gastrointestinal disorder | 25.04 | 19.82 | 13 | 10430 | 2077 | 29562007 |
Liver disorder | 24.71 | 19.82 | 39 | 10404 | 27710 | 29536374 |
Infection | 24.57 | 19.82 | 71 | 10372 | 76680 | 29487404 |
Thrombotic microangiopathy | 24.44 | 19.82 | 22 | 10421 | 8659 | 29555425 |
Engraft failure | 24.11 | 19.82 | 8 | 10435 | 409 | 29563675 |
Product dose omission issue | 23.79 | 19.82 | 3 | 10440 | 96380 | 29467704 |
Ophthalmic vein thrombosis | 23.56 | 19.82 | 5 | 10438 | 42 | 29564042 |
Klebsiella infection | 23.45 | 19.82 | 20 | 10423 | 7329 | 29556755 |
Bacterial toxaemia | 22.32 | 19.82 | 6 | 10437 | 147 | 29563937 |
Tumour lysis syndrome | 22.30 | 19.82 | 26 | 10417 | 13858 | 29550226 |
Antithrombin III decreased | 22.22 | 19.82 | 7 | 10436 | 303 | 29563781 |
Weight decreased | 22.02 | 19.82 | 13 | 10430 | 150892 | 29413192 |
Engraftment syndrome | 21.98 | 19.82 | 9 | 10434 | 834 | 29563250 |
Alternaria infection | 21.85 | 19.82 | 7 | 10436 | 320 | 29563764 |
Neurological symptom | 21.71 | 19.82 | 14 | 10429 | 3356 | 29560728 |
Cerebral ventricle collapse | 21.37 | 19.82 | 5 | 10438 | 68 | 29564016 |
Skin necrosis | 21.01 | 19.82 | 16 | 10427 | 4996 | 29559088 |
Somnolence | 20.76 | 19.82 | 4 | 10439 | 93951 | 29470133 |
Staphylococcal infection | 20.58 | 19.82 | 37 | 10406 | 29203 | 29534881 |
Adenoviral haemorrhagic cystitis | 20.42 | 19.82 | 7 | 10436 | 396 | 29563688 |
Blood bilirubin increased | 20.27 | 19.82 | 40 | 10403 | 33853 | 29530231 |
Device related sepsis | 20.23 | 19.82 | 12 | 10431 | 2483 | 29561601 |
Depression | 20.19 | 19.82 | 3 | 10440 | 85144 | 29478940 |
Disseminated aspergillosis | 20.12 | 19.82 | 7 | 10436 | 414 | 29563670 |
Drug-induced liver injury | 20.06 | 19.82 | 31 | 10412 | 21624 | 29542460 |
Venoocclusive disease | 20.03 | 19.82 | 12 | 10431 | 2527 | 29561557 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 326.74 | 20.43 | 308 | 15449 | 187349 | 64295626 |
Aplastic anaemia | 218.36 | 20.43 | 93 | 15664 | 13827 | 64469148 |
Pre-engraftment immune reaction | 207.10 | 20.43 | 40 | 15717 | 301 | 64482674 |
Multiple organ dysfunction syndrome | 206.50 | 20.43 | 182 | 15575 | 101231 | 64381744 |
Human herpesvirus 6 infection | 175.24 | 20.43 | 59 | 15698 | 4595 | 64478380 |
Encephalitis viral | 168.93 | 20.43 | 49 | 15708 | 2331 | 64480644 |
Aspergillus infection | 163.82 | 20.43 | 80 | 15677 | 16299 | 64466676 |
Acute graft versus host disease | 146.79 | 20.43 | 62 | 15695 | 9022 | 64473953 |
Cytomegalovirus viraemia | 145.87 | 20.43 | 65 | 15692 | 10763 | 64472212 |
Acute graft versus host disease in skin | 131.86 | 20.43 | 53 | 15704 | 6802 | 64476173 |
Bronchopulmonary aspergillosis | 129.88 | 20.43 | 72 | 15685 | 19013 | 64463962 |
Product use in unapproved indication | 125.18 | 20.43 | 183 | 15574 | 176435 | 64306540 |
Mucormycosis | 124.96 | 20.43 | 52 | 15705 | 7289 | 64475686 |
Sepsis | 119.62 | 20.43 | 207 | 15550 | 230134 | 64252841 |
Disseminated intravascular coagulation | 117.92 | 20.43 | 82 | 15675 | 32266 | 64450709 |
Graft versus host disease | 107.59 | 20.43 | 57 | 15700 | 13756 | 64469219 |
Cytomegalovirus infection | 103.26 | 20.43 | 80 | 15677 | 37119 | 64445856 |
Trichosporon infection | 98.56 | 20.43 | 26 | 15731 | 866 | 64482109 |
Respiratory failure | 95.82 | 20.43 | 154 | 15603 | 161029 | 64321946 |
Herpes simplex oesophagitis | 94.97 | 20.43 | 20 | 15737 | 242 | 64482733 |
Pyrexia | 93.73 | 20.43 | 324 | 15433 | 558320 | 63924655 |
Hepatic function abnormal | 93.67 | 20.43 | 96 | 15661 | 64217 | 64418758 |
Cytomegalovirus test positive | 92.85 | 20.43 | 38 | 15719 | 5106 | 64477869 |
Fungal infection | 91.46 | 20.43 | 72 | 15685 | 34179 | 64448796 |
Fungaemia | 89.52 | 20.43 | 34 | 15723 | 3751 | 64479224 |
Pneumonia fungal | 87.67 | 20.43 | 43 | 15714 | 8834 | 64474141 |
Acute graft versus host disease in intestine | 87.46 | 20.43 | 33 | 15724 | 3576 | 64479399 |
Septic shock | 84.58 | 20.43 | 116 | 15641 | 105321 | 64377654 |
Fatigue | 84.30 | 20.43 | 39 | 15718 | 748691 | 63734284 |
Candida infection | 81.64 | 20.43 | 65 | 15692 | 31354 | 64451621 |
Systemic candida | 78.26 | 20.43 | 34 | 15723 | 5295 | 64477680 |
Enterococcal infection | 74.84 | 20.43 | 45 | 15712 | 13821 | 64469154 |
Platelet count decreased | 69.64 | 20.43 | 137 | 15620 | 167574 | 64315401 |
Cytokine release syndrome | 69.40 | 20.43 | 50 | 15707 | 20779 | 64462196 |
Systemic mycosis | 66.45 | 20.43 | 24 | 15733 | 2299 | 64480676 |
Dizziness | 63.13 | 20.43 | 14 | 15743 | 430149 | 64052826 |
Haemophagocytic lymphohistiocytosis | 62.66 | 20.43 | 44 | 15713 | 17565 | 64465410 |
Acute myeloid leukaemia recurrent | 62.22 | 20.43 | 24 | 15733 | 2760 | 64480215 |
Venoocclusive liver disease | 60.60 | 20.43 | 35 | 15722 | 9980 | 64472995 |
Pathogen resistance | 58.27 | 20.43 | 37 | 15720 | 12506 | 64470469 |
Meningoencephalitis herpetic | 57.23 | 20.43 | 20 | 15737 | 1741 | 64481234 |
Arthralgia | 56.27 | 20.43 | 19 | 15738 | 442241 | 64040734 |
Fall | 54.63 | 20.43 | 17 | 15740 | 416809 | 64066166 |
Acute graft versus host disease in liver | 54.21 | 20.43 | 19 | 15738 | 1668 | 64481307 |
Drug resistance | 54.01 | 20.43 | 54 | 15703 | 35048 | 64447927 |
Enterococcal sepsis | 53.96 | 20.43 | 21 | 15736 | 2473 | 64480502 |
Bacterial sepsis | 53.10 | 20.43 | 29 | 15728 | 7428 | 64475547 |
Off label use | 52.17 | 20.43 | 297 | 15460 | 632509 | 63850466 |
Cystitis haemorrhagic | 51.35 | 20.43 | 29 | 15728 | 7927 | 64475048 |
Drug ineffective | 50.01 | 20.43 | 363 | 15394 | 839884 | 63643091 |
Chronic graft versus host disease | 49.15 | 20.43 | 26 | 15731 | 6250 | 64476725 |
Hypoalbuminaemia | 49.00 | 20.43 | 38 | 15719 | 17636 | 64465339 |
Thrombotic microangiopathy | 48.78 | 20.43 | 37 | 15720 | 16618 | 64466357 |
Pain | 48.03 | 20.43 | 39 | 15718 | 553472 | 63929503 |
Fusarium infection | 47.86 | 20.43 | 17 | 15740 | 1552 | 64481423 |
Blood bilirubin increased | 47.13 | 20.43 | 64 | 15693 | 57489 | 64425486 |
Headache | 46.31 | 20.43 | 37 | 15720 | 529430 | 63953545 |
Gastrointestinal fungal infection | 46.19 | 20.43 | 12 | 15745 | 376 | 64482599 |
Engraft failure | 45.23 | 20.43 | 13 | 15744 | 598 | 64482377 |
Bacteraemia | 44.37 | 20.43 | 43 | 15714 | 26868 | 64456107 |
Disseminated aspergillosis | 44.08 | 20.43 | 13 | 15744 | 655 | 64482320 |
Aspartate aminotransferase increased | 43.92 | 20.43 | 93 | 15664 | 119695 | 64363280 |
Renal failure | 43.92 | 20.43 | 120 | 15637 | 181568 | 64301407 |
Lymphoid tissue hypoplasia | 43.39 | 20.43 | 12 | 15745 | 479 | 64482496 |
Staphylococcal sepsis | 43.05 | 20.43 | 31 | 15726 | 12868 | 64470107 |
Cholestatic liver injury | 42.96 | 20.43 | 20 | 15737 | 3659 | 64479316 |
Weissella infection | 42.60 | 20.43 | 7 | 15750 | 17 | 64482958 |
Thymus hypoplasia | 42.42 | 20.43 | 12 | 15745 | 521 | 64482454 |
Pneumonia | 42.40 | 20.43 | 257 | 15500 | 559319 | 63923656 |
Tumour lysis syndrome | 41.70 | 20.43 | 36 | 15721 | 19404 | 64463571 |
Acute respiratory distress syndrome | 40.89 | 20.43 | 49 | 15708 | 38886 | 64444089 |
Sinus polyp | 39.63 | 20.43 | 11 | 15746 | 445 | 64482530 |
Glomerulosclerosis | 39.37 | 20.43 | 13 | 15744 | 952 | 64482023 |
Cerebral aspergillosis | 39.28 | 20.43 | 15 | 15742 | 1678 | 64481297 |
Liver abscess | 38.89 | 20.43 | 21 | 15736 | 5259 | 64477716 |
Mucosal inflammation | 38.76 | 20.43 | 61 | 15696 | 62523 | 64420452 |
Candida sepsis | 38.65 | 20.43 | 16 | 15741 | 2212 | 64480763 |
Pleural effusion | 38.27 | 20.43 | 91 | 15666 | 126468 | 64356507 |
Malaise | 38.12 | 20.43 | 25 | 15732 | 396222 | 64086753 |
Renal impairment | 37.55 | 20.43 | 94 | 15663 | 134923 | 64348052 |
Botulism | 37.40 | 20.43 | 10 | 15747 | 351 | 64482624 |
Delayed graft function | 37.00 | 20.43 | 17 | 15740 | 3019 | 64479956 |
Neutrophil count decreased | 36.87 | 20.43 | 67 | 15690 | 77129 | 64405846 |
Mucosal disorder | 36.86 | 20.43 | 17 | 15740 | 3045 | 64479930 |
Alanine aminotransferase increased | 36.80 | 20.43 | 95 | 15662 | 138936 | 64344039 |
Nasopharyngitis | 36.65 | 20.43 | 3 | 15754 | 196070 | 64286905 |
Product dose omission issue | 36.35 | 20.43 | 3 | 15754 | 194744 | 64288231 |
Cystitis viral | 35.98 | 20.43 | 11 | 15746 | 627 | 64482348 |
Mixed liver injury | 35.43 | 20.43 | 20 | 15737 | 5461 | 64477514 |
Pain in extremity | 35.21 | 20.43 | 15 | 15742 | 303070 | 64179905 |
Immunosuppressant drug level increased | 35.19 | 20.43 | 22 | 15735 | 7237 | 64475738 |
Necrotising oesophagitis | 35.13 | 20.43 | 11 | 15746 | 679 | 64482296 |
White blood cell count decreased | 34.94 | 20.43 | 101 | 15656 | 157736 | 64325239 |
Nasal abscess | 34.71 | 20.43 | 8 | 15749 | 150 | 64482825 |
Dyspnoea | 34.59 | 20.43 | 78 | 15679 | 718596 | 63764379 |
Peripheral swelling | 34.54 | 20.43 | 5 | 15752 | 209148 | 64273827 |
Rhinocerebral mucormycosis | 34.40 | 20.43 | 10 | 15747 | 479 | 64482496 |
Engraftment syndrome | 33.72 | 20.43 | 12 | 15745 | 1101 | 64481874 |
Idiopathic pneumonia syndrome | 33.25 | 20.43 | 10 | 15747 | 539 | 64482436 |
Asthenia | 32.53 | 20.43 | 34 | 15723 | 428010 | 64054965 |
Graft versus host disease in gastrointestinal tract | 32.33 | 20.43 | 19 | 15738 | 5593 | 64477382 |
Blast cell count increased | 32.10 | 20.43 | 12 | 15745 | 1267 | 64481708 |
Geotrichum infection | 32.05 | 20.43 | 11 | 15746 | 907 | 64482068 |
Cytomegalovirus enterocolitis | 31.42 | 20.43 | 12 | 15745 | 1343 | 64481632 |
Staphylococcal infection | 30.83 | 20.43 | 49 | 15708 | 50629 | 64432346 |
Bacterial infection | 30.56 | 20.43 | 34 | 15723 | 24916 | 64458059 |
Graft versus host disease in skin | 30.53 | 20.43 | 18 | 15739 | 5329 | 64477646 |
Adenovirus infection | 30.25 | 20.43 | 20 | 15737 | 7235 | 64475740 |
Lymphocyte count decreased | 29.95 | 20.43 | 43 | 15714 | 40656 | 64442319 |
Graft versus host disease in liver | 29.92 | 20.43 | 12 | 15745 | 1529 | 64481446 |
Plasma cell leukaemia | 29.83 | 20.43 | 12 | 15745 | 1541 | 64481434 |
Disseminated cryptococcosis | 29.73 | 20.43 | 12 | 15745 | 1555 | 64481420 |
Alopecia | 29.72 | 20.43 | 3 | 15754 | 165687 | 64317288 |
Acute lymphocytic leukaemia recurrent | 29.62 | 20.43 | 16 | 15741 | 4010 | 64478965 |
Biloma | 29.49 | 20.43 | 7 | 15750 | 150 | 64482825 |
Klebsiella infection | 29.31 | 20.43 | 25 | 15732 | 13256 | 64469719 |
Oesophagitis | 29.15 | 20.43 | 31 | 15726 | 21599 | 64461376 |
Liver disorder | 28.97 | 20.43 | 49 | 15708 | 53302 | 64429673 |
Nephropathy toxic | 28.90 | 20.43 | 28 | 15729 | 17486 | 64465489 |
Epstein-Barr virus infection | 28.57 | 20.43 | 24 | 15733 | 12464 | 64470511 |
Enterobacter infection | 28.06 | 20.43 | 15 | 15742 | 3681 | 64479294 |
Drug intolerance | 27.77 | 20.43 | 6 | 15751 | 187986 | 64294989 |
Weight increased | 27.37 | 20.43 | 9 | 15748 | 213339 | 64269636 |
Mucosal erosion | 27.29 | 20.43 | 12 | 15745 | 1922 | 64481053 |
Depression | 26.77 | 20.43 | 6 | 15751 | 183285 | 64299690 |
Pseudomembranous colitis | 26.64 | 20.43 | 16 | 15741 | 4900 | 64478075 |
Toxicity to various agents | 26.36 | 20.43 | 30 | 15727 | 363483 | 64119492 |
Acute myeloid leukaemia | 26.30 | 20.43 | 33 | 15724 | 27430 | 64455545 |
Drug-induced liver injury | 26.18 | 20.43 | 44 | 15713 | 47599 | 64435376 |
Hypokalaemia | 26.00 | 20.43 | 77 | 15680 | 121826 | 64361149 |
Rash morbilliform | 25.98 | 20.43 | 16 | 15741 | 5125 | 64477850 |
Blood urea increased | 25.91 | 20.43 | 42 | 15715 | 44111 | 64438864 |
Neutropenic colitis | 25.06 | 20.43 | 15 | 15742 | 4566 | 64478409 |
Device related infection | 24.98 | 20.43 | 34 | 15723 | 30592 | 64452383 |
Neutropenia | 24.79 | 20.43 | 120 | 15637 | 239504 | 64243471 |
Kidney fibrosis | 24.72 | 20.43 | 13 | 15744 | 3088 | 64479887 |
Pruritus | 24.64 | 20.43 | 24 | 15733 | 312376 | 64170599 |
Bacterial toxaemia | 24.13 | 20.43 | 6 | 15751 | 157 | 64482818 |
Leukaemia recurrent | 23.93 | 20.43 | 12 | 15745 | 2582 | 64480393 |
Chest pain | 23.90 | 20.43 | 14 | 15743 | 235966 | 64247009 |
Nausea | 23.86 | 20.43 | 105 | 15652 | 785695 | 63697280 |
Pseudomonal sepsis | 23.38 | 20.43 | 15 | 15742 | 5157 | 64477818 |
Candida test positive | 23.11 | 20.43 | 9 | 15748 | 1061 | 64481914 |
Drug ineffective for unapproved indication | 23.06 | 20.43 | 33 | 15724 | 31100 | 64451875 |
Aspergillus test positive | 22.85 | 20.43 | 8 | 15749 | 700 | 64482275 |
Drug hypersensitivity | 22.85 | 20.43 | 15 | 15742 | 237800 | 64245175 |
Reactive gastropathy | 22.66 | 20.43 | 7 | 15750 | 413 | 64482562 |
Blood pressure increased | 22.63 | 20.43 | 7 | 15750 | 172545 | 64310430 |
Viral haemorrhagic cystitis | 22.61 | 20.43 | 10 | 15747 | 1625 | 64481350 |
Gait disturbance | 22.55 | 20.43 | 7 | 15750 | 172148 | 64310827 |
Hypersensitivity | 22.35 | 20.43 | 10 | 15747 | 196442 | 64286533 |
Oral disorder | 22.19 | 20.43 | 18 | 15739 | 8903 | 64474072 |
Oral fungal infection | 22.06 | 20.43 | 12 | 15745 | 3049 | 64479926 |
Staphylococcal bacteraemia | 21.85 | 20.43 | 19 | 15738 | 10336 | 64472639 |
Overdose | 21.79 | 20.43 | 6 | 15751 | 159560 | 64323415 |
Pulmonary mucormycosis | 21.78 | 20.43 | 8 | 15749 | 804 | 64482171 |
Gamma-glutamyltransferase increased | 21.77 | 20.43 | 41 | 15716 | 48469 | 64434506 |
Pulmonary haemorrhage | 21.71 | 20.43 | 21 | 15736 | 13088 | 64469887 |
Blood lactate dehydrogenase increased | 21.53 | 20.43 | 33 | 15724 | 33045 | 64449930 |
Myocardial infarction | 21.26 | 20.43 | 7 | 15750 | 165814 | 64317161 |
Functional gastrointestinal disorder | 21.24 | 20.43 | 13 | 15744 | 4118 | 64478857 |
Hyperbilirubinaemia | 21.14 | 20.43 | 26 | 15731 | 21179 | 64461796 |
Hypoxia | 21.04 | 20.43 | 58 | 15699 | 88091 | 64394884 |
Cerebral ventricle collapse | 20.44 | 20.43 | 5 | 15752 | 122 | 64482853 |
None
Source | Code | Description |
---|---|---|
ATC | J02AX05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use |
FDA CS | M0519359 | Lipopeptides |
FDA EPC | N0000175507 | Echinocandin Antifungal |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000935 | Antifungal Agents |
CHEBI has role | CHEBI:35441 | antiinfective agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Candidiasis of the esophagus | indication | 20639004 | DOID:13146 |
Disseminated candidiasis | indication | 70572005 | |
Candidal septicemia | indication | 187022007 | |
Candidemia | indication | 432261003 | |
Prevention of Disseminated Candidiasis | indication | ||
Candida Peritonitis | indication | ||
Oropharyngeal Candidiasis | off-label use | ||
Intravascular hemolysis | contraindication | 15601008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Liver function tests abnormal | contraindication | 166603001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.09 | acidic |
pKa2 | 10.7 | acidic |
pKa3 | 12.91 | acidic |
pKa4 | 13.44 | acidic |
pKa5 | 13.52 | acidic |
pKa6 | 13.9 | acidic |
pKa7 | 13.91 | acidic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 100MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | June 27, 2006 | RX | INJECTABLE | INTRAVENOUS | Dec. 20, 2022 | TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE |
EQ 50MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | March 16, 2005 | RX | INJECTABLE | INTRAVENOUS | Dec. 20, 2022 | TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE |
EQ 100MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | June 27, 2006 | RX | INJECTABLE | INTRAVENOUS | June 20, 2023 | PEDIATRIC EXCLUSIVITY |
EQ 50MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | March 16, 2005 | RX | INJECTABLE | INTRAVENOUS | June 20, 2023 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1,3-glucan synthase catalytic subunit 1 | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Beta-1,3-glucan synthase | Unclassified | WOMBAT-PK |
ID | Source |
---|---|
D02465 | KEGG_DRUG |
208538-73-2 | SECONDARY_CAS_RN |
4024920 | VANDF |
4024948 | VANDF |
C1120386 | UMLSCUI |
CHEBI:600520 | CHEBI |
CHEMBL457547 | ChEMBL_ID |
CHEMBL1237070 | ChEMBL_ID |
D000077551 | MESH_DESCRIPTOR_UI |
DB01141 | DRUGBANK_ID |
8069 | INN_ID |
R10H71BSWG | UNII |
477468 | PUBCHEM_CID |
325887 | RXNORM |
19567 | MMSL |
334346 | MMSL |
66902 | MMSL |
d05487 | MMSL |
010714 | NDDF |
010715 | NDDF |
416127003 | SNOMEDCT_US |
416233001 | SNOMEDCT_US |
426226002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9361 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9362 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-190 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 29 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-191 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 29 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-229 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 26 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-230 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 26 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6119 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6120 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-728 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-729 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-729 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-036 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 34 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-037 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 34 sections |